The statements contained herein include forward-looking statements. Although we believe our expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted.
The forward-looking statements reflect knowledge and information available at the date of the preparation of this press release and the Company undertakes no obligation to update these forward-looking statements.
Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond our control, include, among other things, those risk factors identified in the Company's Annual Report/Form 20-F for 2007. Nothing contained herein should be construed as a profit forecast.
ONGLYZA is a trademark of the Bristol-Myers Squibb Company.
References
1. Rosenstock J, et al. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naïve patients with type 2 diabetes. Diabetes, Obesity and Metabolism 2008; 10: 376-386
2. De Fronzo, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes on metformin alone. Diabetes Care 2009: published ahead of print May 28, 2009, doi:10.2337/dc08-1984
3. Ravichandran S, et al. Saxagliptin Added to a Sulfonylurea is Safe and More Efficacious Than Up-titrating a Sulfonylurea in Patients with Type 2 Diabetes. Abstract presented at EASD, 2008
4. Allen E, et al. Saxagliptin Added To A Thiazolidinedione Improves Glycemic Control In Patients With Inadequately Controlled Type 2 Diabetes. Abstract presented at EASD, 2008
5. Jadzinsky M, et al. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes, Obesity and Metabolism 2009; 11: 611-622
6. International Diabetes Federation factsheet "diabetes prevalence" accessed 19 May, 2009 http://www.idf.org/diabetes-prevalence
7. IDF Global Guideline for type 2 diabetes 2005: Chapter 6: glucose control levels accessed 19 May, 2009 http://www.idf.org/webdata/docs/IDF%20GG...
Contacts: Media: Bristol-Myers Squibb, Carmel Hogan, +33-674-107-658, Carmel.hogan@bms.com OR AstraZeneca, Neil McCrae, +44-207-304-5045, Neil.mccrae@astrazeneca.com; Investors: Bristol-Myers Squibb, John Elicker, +1-609-252-4611, John.elicker@bms.com OR AstraZeneca, Edward Seage, +1-302-886-4065, Edward.seage@astrazeneca.com; Jonathan Hunt, +44-777-570-4032, Jonathan.hunt@astrazeneca.com
